Skip to content

Study · Systematic review · 2025

5 results

Cardiovascular Safety Profile of Semaglutide and Variations by Sex, Race, and Kidney Function: A Systematic Review and Meta-analysis.

Hamayal M, Akhtar CH, Ahmad N, Awwab M, Shahid W, Abbasi HS, Nadeem E, Siddiqui E, Zafar W, Hussain S

American journal of cardiovascular drugs : drugs, devices, and other interventions19 Mar 2025Cited by 1 (Europe PMC)

PMID40106161 (opens in a new tab)DOI10.1007/s40256-025-00727-y (opens in a new tab)PepBankPUB-40106161
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In patients with established or at risk of cardiovascular disease, semaglutide lowered the risk of MACE (risk ratio 0.81).

    In plain wordsIn patients with or at risk of heart disease, semaglutide lowered the risk of major heart events across four trials.

    Peptide
    Semaglutide
    Outcome
    DecreaseMajor adverse cardiovascular events (MACE)
    Study

    n: not reported in source

    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Risk ratio, MACE
    0.81
    95% CI 0.74-0.88

    Source sentences

    Summary
    The risk of MACE with semaglutide was significantly lower in patients with established or a risk of cardiovascular disease (risk ratio [RR] 0.81; 95% confidence interval [CI] 0.74-0.88; p < 0.00001).
    2 context sentences
    Summary · context
    We searched the PubMed, Cochrane Library, and Clinicaltrials.gov databases and included randomized controlled trials (RCTs) where semaglutide was the intervention and major adverse cardiovascular events (MACE) or expanded MACE was the outcome.
    Summary · context
    Of 5387 articles, four RCTs were included.
  2. 02HumanSystematic reviewEfficacy outcome

    In four RCTs, semaglutide lowered the risk of expanded MACE (risk ratio 0.80).

    In plain wordsAcross four trials, semaglutide lowered the risk of an expanded set of major heart events.

    Peptide
    Semaglutide
    Outcome
    DecreaseExpanded MACE
    Study

    n: not reported in source

    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Risk ratio, expanded MACE
    0.8
    95% CI 0.75-0.86

    Source sentences

    Summary
    The risk of expanded MACE also reduced significantly with semaglutide (RR 0.80; 95% CI 0.75-0.86; p < 0.00001).
    2 context sentences
    Summary · context
    We searched the PubMed, Cochrane Library, and Clinicaltrials.gov databases and included randomized controlled trials (RCTs) where semaglutide was the intervention and major adverse cardiovascular events (MACE) or expanded MACE was the outcome.
    Summary · context
    Of 5387 articles, four RCTs were included.
  3. 03HumanSystematic reviewEfficacy outcome

    In males, semaglutide lowered the risk of MACE (risk ratio 0.78).

    In plain wordsIn men, semaglutide was linked to a lower risk of major heart events in a meta-analysis of trials.

    Peptide
    Semaglutide
    Outcome
    DecreaseMACE in males
    Study

    n: not reported in source

    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Risk ratio, MACE, males
    0.78
    95% CI 0.70-0.87

    Source sentences

    Summary
    MACE risk reduction was significant in males (RR 0.78; 95% CI 0.70-0.87; p < 0.00001)
    2 context sentences
    Summary · context
    We searched the PubMed, Cochrane Library, and Clinicaltrials.gov databases and included randomized controlled trials (RCTs) where semaglutide was the intervention and major adverse cardiovascular events (MACE) or expanded MACE was the outcome.
    Summary · context
    Of 5387 articles, four RCTs were included.
  4. 04HumanSystematic reviewEfficacy outcome

    In Asian populations, semaglutide lowered the risk of MACE (risk ratio 0.61).

    In plain wordsIn Asian people, semaglutide was linked to a lower risk of major heart events in a meta-analysis of trials.

    Peptide
    Semaglutide
    Outcome
    DecreaseMACE in Asian populations
    Study

    n: not reported in source

    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Risk ratio, MACE, Asian
    0.61
    95% CI 0.44-0.83

    Source sentences

    Summary
    in Asian (RR 0.61; 95% CI 0.44-0.83; p = 0.002)
    2 context sentences
    Summary · context
    We searched the PubMed, Cochrane Library, and Clinicaltrials.gov databases and included randomized controlled trials (RCTs) where semaglutide was the intervention and major adverse cardiovascular events (MACE) or expanded MACE was the outcome.
    Summary · context
    Of 5387 articles, four RCTs were included.
  5. 05HumanSystematic reviewEfficacy outcome

    In white populations, semaglutide lowered the risk of MACE (risk ratio 0.82).

    In plain wordsIn white people, semaglutide was linked to a lower risk of major heart events in a meta-analysis of trials.

    Peptide
    Semaglutide
    Outcome
    DecreaseMACE in white populations
    Study

    n: not reported in source

    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Risk ratio, MACE, white
    0.82
    95% CI 0.73-0.90

    Source sentences

    Summary
    white (RR 0.82; 95% CI 0.73-0.90; p = 0.0001)
    2 context sentences
    Summary · context
    We searched the PubMed, Cochrane Library, and Clinicaltrials.gov databases and included randomized controlled trials (RCTs) where semaglutide was the intervention and major adverse cardiovascular events (MACE) or expanded MACE was the outcome.
    Summary · context
    Of 5387 articles, four RCTs were included.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.